Milan, May 31 (beraking latest news Health) – New data demonstrate the benefits of ibrutinib in chronic lymphocytic leukemia (CLL) patients, both in combination and as monotherapy. Janssen, a pharmaceutical company of the American group Johnson & Johnson, will present the new results at the 2021 Congress of Asco, the American Society of Clinical Oncology.
The Phase 2 Captivate study, in the cohort of patients with fixed duration treatment of ibrutinib plus venetoclax – summarizes the company in a note – shows that 95% of treated patients survive progression-free after 2 years, with significant remissions in all subgroups, including patients with high-risk LLC. Furthermore, the long-term results of the Resonate-2 study, which to date represents the longest phase 3 follow-up, of 7 years, for Bruton tyrosine kinase (Btk) inhibitors, indicate a strengthening of the benefits in terms of long-term survival and an established safety profile of ibrutinib monotherapy for patients with CLL, a type of non-Hodgkin’s lymphoma and the most common form of leukemia in adults.
“The positive results of the Captivate study – says Craig Tendler, Vice President, Clinical Development and Global Medical Affairs, Oncology, Janssen Research & Development – demonstrate the potential of ibrutinib plus venetoclax therapy, thanks to a complementary mechanism of action, to induce deep responses in combination with fixed duration once daily, regimen that can be administered in the office for younger and healthy patients. While “the results of Resonate-2 – he adds – further support the long-term benefit of monotherapy with ibrutinib in the first line in patients with CLL. The breadth and importance of the growing number of data continues to indicate this treatment as a standard of care and to enhance its impact on progression-free and overall survival “.
“Continuous treatment with ibrutinib in patients with CLL is now an established standard of care, also used in those at high risk – comments Paolo Ghia, professor of medical oncology at the Vita-Salute San Raffaele University in Milan and principal investigator of the study. Captivate – The latest data from the study emphasize that ibrutinib, administered orally in combination with venetoclax, also results in a high 2-year progression-free survival rate, allowing patients to remission without treatment. “
“Ibrutinib – recalls Edmond Chan, Emea Therapeutic Area Lead Haematology, Janssen-Cilag Ltd – was the first Btk inhibitor approved in Europe and has been used in the treatment of over 230 thousand patients worldwide. It is also the first inhibitor of Btk. Btk studied in a combined treatment with a fixed duration. The latest data to be presented at Asco reinforce the potential of ibrutinib as a key treatment option across the whole CLL landscape and add further evidence on its efficacy and safety profile “.